Jump to section
To solve biological inaccessibility.
Founded out of research at the University of Cambridge, Nuclera is a biotech company developing protein-printing technologies to make proteins more accessible to everyone. In doing so, the bioprinter company enables life science researchers to accelerate breakthrough improvements in human health due to better access to biomolecules.
The company is somewhat revolutionary seeing as developing proteins has long been a time-consuming and complicated process. Rather than taking weeks, months, or years, Nuclera’s eProtein desktop bioprinting technology does so in hours.
Trust in the product is marked by substantial funding between 2018 and 2022, which is being invested into accelerating the development and commercialization of the eProtein desktop bioprinter.
Freddie
Company Specialist at Welcome to the Jungle
Oct 2024
$75m
SERIES C
Jun 2024
$1.4m
GRANT
This company has top investors
Gordon McInroy
(CTO)Previously acted as a Postdoctoral Research Associate for the University of Cambridge, before founding and acting as CSO for Nuclera.
Jiahao Huang
(CFO)Previously acted as a Research Analyst for Strategic Partnerships Office for the University of Cambridge.
Michael Chen
(CEO)Previously studied at the University of Cambridge, National Institutes of Health, and Georgia Institute of Technology.